Table 1 Baseline criteria of the two groups before PSM

Patients, n

62

150

Age (year)^a

70.4 ± 7.0

73.2 ± 6.5

0.027

Disease duration (year)^a

5.2 ± 2.2

6.6 ± 3.2

0.006

Anticoagulants^b

13 (21%)

35 (23.3%)

0.708

Alpha blockers^b

32 (51.6%)

78 (52%)

0.959

5ARIs alone or combined with alpha blockers^b

22 (35.5%)

58 (38.7%)

0.664

Urogenital complications

 With acute urinary retention^b

17 (27.4%)

47 (31.3%)

0.572

 With gross haematuria^b

19 (30.6%)

47 (31.3%)

0.992

 With bladder stones^b

12 (21.3%)

32 (21.3%)

0.747

 With bladder trabeculae or chambers^b

33 (53.2%)

81 (54%)

0.918

Prostate volume (ml)^a

63.4 ± 20.2

69.4 ± 14.9

0.004

IPSS^a

24.6 ± 4.8

26.2 ± 4.7

0.009

QoL^a

4.9 ± 0.8

4.7 ± 0.8

0.047

Qmax (ml/s)^a

6.3 ± 2.4

7.6 ± 2.3

0.001

PVR (ml)^a

147.2 ± 139.8

135.5 ± 124.3

0.662

PSA (ng/ml)^a

4.0 ± 2.5

4.0 ± 2.0

0.776